What Investors Should Know of This Doximity Officer's Latest Insider Transaction
Key Points
The transaction involved the exercise of options and a subsequent disposition valued at $140,400 at $24.84 per share.
The activity was split between a Rule 10b5-1 trading plan sale to cover tax obligations and mandated shares withheld by the issuer for restricted stock unit vesting.
The move reflects routine tax-driven liquidity rather than a discretionary change in investment thesis.
- 10 stocks we like better than Doximity ›
Chief Accounting Officer Siddharth Sitaram disposed of 5,652 shares of Doximity, Inc. (NYSE:DOCS) for a total value of $140,400 on August 13 and August 15, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $140,400 |
| Shares sold | 5,652 |
| Post-transaction shares (directly held) | 93,122 |
| Post-transaction value | $2.31 million |
Transaction value based on SEC Form 4 weighted average sale price ($24.84).
Key questions
- What was the primary driver of this transaction?
The activity was non-discretionary and focused on tax management, consisting of 3,882 shares withheld by the issuer to cover restricted stock unit vesting and 1,770 shares sold under a Rule 10b5-1 plan to satisfy tax obligations from an option exercise. - What is the insider's remaining equity position in the company?
Sitaram maintains direct ownership of 93,122 shares and also holds 59,000 derivative securities. - How has the company performed financially as of the transaction date?
Doximity reported trailing 12-month revenue of $655.6 million and net income of $167.0 million, with a market capitalization of $4.6 billion as of the August 14 market close.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-14) | $24.80 |
| Market Capitalization | $4.6 billion |
| Revenue (TTM) | $655.6 million |
| Net Income (TTM) | $167.0 million |
Company Snapshot
- Doximity operates a cloud-hosted digital platform that provides healthcare practitioners with specialized tools for peer connectivity, patient care coordination, remote consultations, access to medical research, and professional development.
- The company generates revenue through subscription-based services and licensing arrangements with pharmaceutical companies and healthcare organizations that utilize the platform to engage with medical professionals.
- The primary customer base consists of pharmaceutical companies seeking to reach physicians and healthcare organizations seeking to optimize clinical workflows and practitioner engagement across the United States healthcare system.
Doximity is a leading digital health platform serving the U.S. healthcare practitioner community with approximately 880 employees and a market capitalization of $4.6 billion. The company has achieved substantial profitability with TTM net income of $167.0 million on revenue of $655.6 million, demonstrating strong unit economics and operational efficiency. Doximity's competitive advantage derives from its comprehensive practitioner network, integrated suite of clinical and professional tools, and established relationships with pharmaceutical and healthcare organization customers.
What this transaction means for investors
Sitaram did a version of this in mid-July too, exercising a slice of the same $4.12 options and selling just enough to cover what he owed. August was effectively the same again with RSU withholding stacked on top, so this certainly seems routine.
The interesting part is that executive equity has stopped being a footnote in Doximity's actual results. The GAAP effective tax rate ran about 40% in the June quarter against 17% a year earlier, which CFO Matt Sonefeldt tied on the August 6 call to how equity compensation is taxed. That's a meaningful chunk of why GAAP earnings came in at $0.13 a share versus $0.27, while the non-GAAP number was $0.29. The gap between those two figures is wider than usual, and it isn't closing this year.
Meanwhile, Doximity didn't recognize AI search revenue in the June quarter, though the compute costs behind the usage were already in cost of revenue, dragging gross margin to 87.5% from 91.2%. Co-founder and CEO Jeff Tangney said on the call that "we're earning more than 10x per search in revenue than it cost us." That's attractive economics despite a revenue base of zero so far. Next quarter will look to change that.
Should you buy stock in Doximity right now?
Before you buy stock in Doximity, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Doximity wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $421,511!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,960!*
Now, it’s worth noting Stock Advisor’s total average return is 981% — a market-crushing outperformance compared to 216% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 18, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Doximity. The Motley Fool has a disclosure policy.
Recommended Articles
